{
    "organizations": [],
    "uuid": "216b8e9b7465bba672b67d2f81331162dff881a2",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-beigene-and-mirati-therapeutics-an/brief-beigene-and-mirati-therapeutics-announce-exclusive-license-agreement-for-sitravatinib-in-the-asia-pacific-region-idUSFWN1P30HN",
    "ord_in_thread": 0,
    "title": "BRIEF-Beigene And Mirati Therapeutics Announce Exclusive License Agreement For Sitravatinib In The Asia Pacific Region",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 8 (Reuters) - Beigene Ltd:\n* BEIGENE AND MIRATI THERAPEUTICS ANNOUNCE EXCLUSIVE LICENSE AGREEMENT FOR SITRAVATINIB IN THE ASIA PACIFIC REGION\n* BEIGENE LTD - MIRATI WILL RETAIN EXCLUSIVE RIGHTS FOR DEVELOPMENT, MANUFACTURING AND COMMERCIALIZATION OF SITRAVATINIB FOR REST OF WORLD.\n* BEIGENE LTD - UNDER AGREEMENT MIRATI WILL RECEIVE AN UPFRONT CASH PAYMENT OF $10 MILLION FROM BEIGENE\n* BEIGENE - MIRATI ELIGIBLE TO RECEIVE UP TO $123 MILLION OF EXTRA PAYMENTS UPON CERTAIN DEVELOPMENT, REGULATORY AND SALES MILESTONES, AMONG OTHERS\n* BEIGENE - CO, MIRATI THERAPEUTICS ENTERED AGREEMENT FOR DEVELOPMENT, MANUFACTURING, COMMERCIALIZATION OF MIRATIâ€˜S SITRAVATINIB IN ASIA Source text for Eikon: Further company coverage:\n ",
    "published": "2018-01-08T19:08:00.000+02:00",
    "crawled": "2018-01-09T17:08:48.024+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "beigene",
        "ltd",
        "beigene",
        "mirati",
        "therapeutic",
        "announce",
        "exclusive",
        "license",
        "agreement",
        "sitravatinib",
        "asia",
        "pacific",
        "region",
        "beigene",
        "ltd",
        "mirati",
        "retain",
        "exclusive",
        "right",
        "development",
        "manufacturing",
        "commercialization",
        "sitravatinib",
        "rest",
        "world",
        "beigene",
        "ltd",
        "agreement",
        "mirati",
        "receive",
        "upfront",
        "cash",
        "payment",
        "million",
        "beigene",
        "beigene",
        "mirati",
        "eligible",
        "receive",
        "million",
        "extra",
        "payment",
        "upon",
        "certain",
        "development",
        "regulatory",
        "sale",
        "milestone",
        "among",
        "others",
        "beigene",
        "co",
        "mirati",
        "therapeutic",
        "entered",
        "agreement",
        "development",
        "manufacturing",
        "commercialization",
        "mirati",
        "sitravatinib",
        "asia",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}